MX2016013434A - Inhibidores potentes y selectivos del virus de la hepatitis c. - Google Patents
Inhibidores potentes y selectivos del virus de la hepatitis c.Info
- Publication number
- MX2016013434A MX2016013434A MX2016013434A MX2016013434A MX2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- hepatitis
- potent
- selective inhibitors
- compounds
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 4
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos, composiciones y métodos para tratar o prevenir la infección por el virus de la hepatitis C (HCV) en sujetos humanos u otros huéspedes animales. Los compuestos son también sales profármacos farmacéuticamente aceptables y otros derivados de los mismos como composiciones farmacéuticas y métodos para el tratamiento o la prevención de la infección por el HCV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461980016P | 2014-04-15 | 2014-04-15 | |
| PCT/US2015/025903 WO2015160907A2 (en) | 2014-04-15 | 2015-04-15 | Potent and selective inhibitors of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016013434A true MX2016013434A (es) | 2017-03-03 |
Family
ID=54324704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013434A MX2016013434A (es) | 2014-04-15 | 2015-04-15 | Inhibidores potentes y selectivos del virus de la hepatitis c. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9926295B2 (es) |
| EP (1) | EP3131892A4 (es) |
| JP (1) | JP2017513852A (es) |
| KR (1) | KR20170002407A (es) |
| CN (1) | CN106661004A (es) |
| AU (1) | AU2015247706A1 (es) |
| BR (1) | BR112016023833A2 (es) |
| CA (1) | CA2945514A1 (es) |
| IL (1) | IL248318A0 (es) |
| MX (1) | MX2016013434A (es) |
| PH (1) | PH12016502039A1 (es) |
| RU (1) | RU2016144076A (es) |
| SG (1) | SG11201608587QA (es) |
| WO (1) | WO2015160907A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| WO2015009744A1 (en) | 2013-07-17 | 2015-01-22 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US11752166B2 (en) | 2018-05-09 | 2023-09-12 | Cocrystal Pharma, Inc. | Combination therapy for treatment of HCV |
| CN109456375B (zh) * | 2018-12-11 | 2019-10-22 | 枣庄学院 | 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5312486B2 (ja) * | 2008-02-13 | 2013-10-09 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| CA2751458C (en) * | 2009-02-06 | 2018-06-05 | Rfs Pharma, Llc | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
| US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BR112013004520A2 (pt) * | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| WO2012048421A1 (en) * | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| JP5828903B2 (ja) * | 2010-11-01 | 2015-12-09 | アールエフエス ファーマ，エルエルシー | 新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤 |
-
2015
- 2015-04-15 JP JP2016562874A patent/JP2017513852A/ja active Pending
- 2015-04-15 KR KR1020167030815A patent/KR20170002407A/ko not_active Withdrawn
- 2015-04-15 BR BR112016023833A patent/BR112016023833A2/pt active Search and Examination
- 2015-04-15 US US15/303,277 patent/US9926295B2/en active Active
- 2015-04-15 MX MX2016013434A patent/MX2016013434A/es unknown
- 2015-04-15 RU RU2016144076A patent/RU2016144076A/ru unknown
- 2015-04-15 CN CN201580032237.0A patent/CN106661004A/zh active Pending
- 2015-04-15 SG SG11201608587QA patent/SG11201608587QA/en unknown
- 2015-04-15 CA CA2945514A patent/CA2945514A1/en not_active Abandoned
- 2015-04-15 EP EP15779578.2A patent/EP3131892A4/en not_active Withdrawn
- 2015-04-15 WO PCT/US2015/025903 patent/WO2015160907A2/en not_active Ceased
- 2015-04-15 AU AU2015247706A patent/AU2015247706A1/en not_active Abandoned
-
2016
- 2016-10-12 PH PH12016502039A patent/PH12016502039A1/en unknown
- 2016-10-13 IL IL248318A patent/IL248318A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170029407A1 (en) | 2017-02-02 |
| IL248318A0 (en) | 2016-11-30 |
| US9926295B2 (en) | 2018-03-27 |
| JP2017513852A (ja) | 2017-06-01 |
| KR20170002407A (ko) | 2017-01-06 |
| EP3131892A2 (en) | 2017-02-22 |
| RU2016144076A (ru) | 2018-05-16 |
| CA2945514A1 (en) | 2015-10-22 |
| AU2015247706A1 (en) | 2016-10-27 |
| BR112016023833A2 (pt) | 2017-10-10 |
| WO2015160907A2 (en) | 2015-10-22 |
| SG11201608587QA (en) | 2016-11-29 |
| EP3131892A4 (en) | 2017-09-20 |
| PH12016502039A1 (en) | 2017-01-09 |
| CN106661004A (zh) | 2017-05-10 |
| WO2015160907A3 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210109A1 (ar) | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| WO2012027712A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| UA117518C2 (uk) | 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b | |
| PH12018500576A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
| PH12018502077A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12018502015A1 (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| EA201892216A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| MX2018011786A (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue. | |
| PH12016502039A1 (en) | Potent and selective inhibitors of hepatitis c virus | |
| NZ733313A (en) | Indole derivatives as dengue viral replication inhibitors | |
| EA201790700A1 (ru) | Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MY185672A (en) | Mono-or di-substituted indole derivatives as dengue viral replication inhibitors | |
| MY197383A (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |